Skip to main content
Viva Biotech Holdings logo

Viva Biotech Holdings — Investor Relations & Filings

Ticker · 1873 ISIN · KYG9390W1015 LEI · 300300VJBVYQ6XJUKY15 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 487 across all filing types
Latest filing 2026-05-26 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1873

About Viva Biotech Holdings

http://www.vivabiotech.com

Viva Biotech Holdings provides comprehensive, integrated drug discovery, development, and manufacturing services (CRO/CDMO) to global biotechnology and pharmaceutical clients. The company operates a leading Structure-Based Drug Discovery (SBDD) platform, supporting innovative drug programs from early-stage preclinical research through to commercialization. Core services encompass protein expression and structure determination, hits screening, therapeutic antibody discovery, computer-aided drug design (CADD), medicinal chemistry, custom synthesis, and ADME/PK studies. This one-stop service model facilitates the entire drug development lifecycle for its worldwide customer base.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 91% confidence The document is a regulatory Form FF305 “Next Day Disclosure Return” detailing changes in issued shares and treasury shares, including multiple share repurchase transactions, dates, volumes, prices, and confirmations. It is a report of the company’s own share buybacks on-market under Hong Kong Listing Rules, and contains detailed transactional data rather than an announcement of an upcoming report. This aligns precisely with the “Transaction in Own Shares” category.
2026-05-26 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” form FF305, detailing changes in issued and treasury shares, multiple share repurchases (on‐market buybacks) and confirmations under Main Board Rule 13.25A / GEM Rule 17.27A and Main Board Rule 10.06 / GEM Rule 13.13. It is a regulatory announcement of actual repurchase transactions (the company buying back its own shares), fitting the definition “Transaction in Own Shares” (POS).
2026-05-22 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 88% confidence The document is a "Next Day Disclosure Return" (Form FF305) required under Hong Kong Listing Rules, detailing changes in issued shares and treasury shares as well as on‐market repurchases of the company’s own shares. It provides specific data on share buybacks, repurchase prices, and treasury share movements. This is a regulatory disclosure of transactions in the company’s own shares (share repurchases/issuances), matching the definition of Transaction in Own Shares (Code: POS).
2026-05-21 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Exchange “Next Day Disclosure Return” (Form FF305) disclosing changes in issued shares, treasury shares, and on-market repurchases of shares by Viva Biotech. It provides detailed repurchase volumes, prices, and confirmations under HKEX Main Board/GEM rules. This matches the definition for Transaction in Own Shares – a report of the company buying back or selling its own shares. Therefore, the appropriate filing category is POS.
2026-05-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases, including dates, prices, and quantities. The document also includes confirmations regarding compliance with listing rules and legal requirements. The content is focused on reporting share repurchase activities and changes in share capital, not on financial results, management commentary, or other report types. This matches the definition of a 'Transaction in Own Shares' filing, which covers company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2026-05-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Stock Exchange rules detailing changes in issued shares, treasury share transactions, and share repurchase activity by the issuer. It is a regulatory disclosure of transactions in the company’s own shares (buybacks and on-market sales of treasury shares). This aligns directly with the ‘Transaction in Own Shares’ category (Code: POS).
2026-05-18 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.